Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
The company’s latest results and guidance increase fueled optimism, even as traders increasingly look for additional upside from a next-generation weight-loss pipeline asset that is not yet a mainstream Wall Street headline.
THE APEX TIMES
THE APEX TIMES
The U.K. regulator has authorized Eli Lilly’s oral weight-management and type 2 diabetes drug, making Britain the first country in Europe to clear the medicine, according to a market report.
THE APEX TIMES
The UK’s medicines regulator, MHRA, has given Lilly’s Foundayo a regulatory green light, while the European Union review is still ongoing. The move is expected to raise the competitive stakes in a crowded obesity and weight-management market dominated by injectable medicines and expanding pipeline bets.
THE APEX TIMES
Veeva Systems said Eli Lilly has committed to deploy Vault CRM globally, indicating continued investment in cloud-based tools that manage sales and customer engagement in life sciences.
THE APEX TIMES
Eli Lilly’s LLY shares have reflected investor enthusiasm for GLP-1 medicines, and a televised discussion highlighted a view that the market’s momentum may have years left, not quarters.
THE APEX TIMES
The FDA authorization for J&J’s OTTAVA soft-tissue robotic surgery system and ongoing movement around talc litigation and settlements may change how investors weigh near-term growth versus headline legal exposure.
THE APEX TIMES
A market commentary in Yahoo Finance weighed how a legal settlement involving Arbutus Biopharma Corporation and Moderna, Inc. might be leveraged commercially, but offered limited specifics on the deal itself.
THE APEX TIMES
An updated “fair value” reference point for Eli Lilly shares was lifted from about $1,270 to roughly $1,297, according to a market update published by Yahoo Finance on August 10, 2026. The change was linked to revised assumptions around GLP-1-related earnings expectations.
THE APEX TIMES
The Massachusetts senator argues that tight ties between insurers and pharmacy benefits, including UnitedHealth and CVS, concentrate control, raise costs, and boost corporate profits. Her comments land as scrutiny of pricing and consolidation remains a live political issue.
